2013 will be an exciting year for Array BioPharma Inc. (ARRY) as it transitions into a late-stage development company. It has a diverse pipeline of drugs with up to six potential Phase III decisions over the next year. ARRY also enjoys potentially lucrative partnerships with several large pharmaceutical companies, including Amgen (AMGN), Astra Zeneca (AZN), Celgene (CELG), Genentech, and Novartis (NVS). The potential for significant milestone and royalty revenue from these partnerships is offset by the length of time before any of the drugs may reach commercialization and the inherent risks of drug development.
Source: March 2013 Investor Presentation
ARRY currently has four drugs in...
Only subscribers can access this article, which is part of the PRO research library covering 3,773 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: